Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Hoffmann-La Roche

Clinicaltrial registered30 Oct 2026

Hoffmann-La Roche

30 Oct 2026: Trial registered · A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
30 Oct 2026
Title
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
Conditions
Solid Tumors
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07905924
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Hoffmann-La Roche

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Hoffmann-La Roche in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.